FINANCIAL CALENDAR 2026
Paiania, 05 March 2026 - Lavipharm S.A., pursuant to articles 4.1.2 & 4.1.3.15.1 of the Athens Stock Exchange Rulebook, announces its Financial Calendar for 2026, as follows.. FINANCIAL CALENDAR 2026...
Paiania, 05 March 2026 - Lavipharm S.A., pursuant to articles 4.1.2 & 4.1.3.15.1 of the Athens Stock Exchange Rulebook, announces its Financial Calendar for 2026, as follows.. FINANCIAL CALENDAR 2026...
Peania, November 17, 2025 – Lavipharm S.A. informs the investment community of the Group’s key consolidated financial figures for the nine-month period of 2025. Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) from continuing and discontinued operations increased by 11.2%, reaching €10.47 million compared...
Financial Results for the First Half of 2025 – Steady Growth Momentum Peania, September 18, 2025 – Lavipharm Group reports an increase in its consolidated sales during the First Half of 2025. Specifically, consolidated sales from continuing operations amounted to €31.0 million, compared to €29.3 million...
Paiania, 3 July 2025 - Lavipharm S.A. (LAVI) held its Annual General Meeting at the company’s headquarters in Paiania, with a quorum achieved, as 34 shareholders representing 70,34% of the share capital were present. CEO Tilemachos Lavidas opened the session by welcoming shareholders and announcing...
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) Increased by 32.4% Paiania, 15 May 2025 – Lavipharm Group’s total earnings before interest, taxes, depreciation, and amortization (EBITDA) for the First Quarter of 2025 increased by 32.4%, amounting to EUR 3.77 million compared to EUR 2.85 million...
Peania, 23 January 2025 – Lavipharm announces a strategic commercial agreement with the multinational company iNova Pharmaceuticals, the owner of Betadine® and other trusted brands. The new partnership involves the licensing rights of a new antiseptic pharmaceutical OTC product developed by Lavipharm to be commercialized by...
Athens, 23.01.2024 – FAMAR and Lavipharm, two prominent companies in the pharmaceutical industry, jointly announce their new collaboration. FAMAR is a leading provider of development and manufacturing services for pharmaceutical and cosmetic products (CDMO) and one of the major CDMO players in Europe. Lavipharm, a...